Medizinische Hochschule Hannover
Medizinische Hochschule Hannover is recorded as a service provider in 34 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 34 trials · Latest update first
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
MRD registry and multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or CLL (RESOLVE trial).
Sponsor Medizinische Hochschule Hannover
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial
Sponsor GWT-Tud GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
B-NHL 2013 - Treatment protocol for mature aggressive B-cell lymphoma and leukemia in children and adolescents
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
LBL 2018 – International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
Long-term follow-up of patients treated with GD2IL18CART
Sponsor Universitaet Muenster
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant Dynamic marker - adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk, HR+/HER2- early breast cancer (ADAPTcycle)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
Sponsor Universitaetsklinikum Schleswig-Holstein AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
Sponsor Medical Center - University Of Freiburg
- Start (EU)
- Latest update
- Estimated end
- Not reported
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer (ADAPT-TN-III)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An interventional, open-label, phase III study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside standard-of-care endocrine treatment in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment (CAPIcorn)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer (ADAPT-HER2-IV)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Medizinische Hochschule Hannover?
The 2026-10-09 snapshot links Medizinische Hochschule Hannover to 34 distinct CTIS trials. Recorded services include Laboratory services, Data management, Statistical analysis, Regulatory services, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Medizinische Hochschule Hannover?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Blood Disorders, Gynecology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Medizinische Hochschule Hannover conducted?
The linked trials record locations in 20 countries, including Germany, Austria, Spain, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Medizinische Hochschule Hannover delivered services.
What can this page tell me about Medizinische Hochschule Hannover's trial experience?
Browse 34 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Medizinische Hochschule Hannover. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Medizinische Hochschule Hannover